By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today announced that it will split into two separate, publicly-traded companies — one focused on diversified medical products and the other on research-based pharmaceuticals.

The diversified medical products business, which includes the branded generic pharmaceutical, medical devices, diagnostics (including molecular diagnostics), and nutritional businesses, will retain the Abbott name. These businesses combined bring in annual revenues of roughly $22 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.